Ovarian Adenocarcinoma — Research

Ovarian Adenocarcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-13	1,623	`("Ovarian Adenocarcinoma"[tiab] OR "Adenocarcinoma of Ovary"[tiab] OR "Adenocarcinoma of the Ovary"[tiab])`	2026-09-13	pubmed
Last 5 years	2021-01-01 → 2026-12-31	227	`("Ovarian Adenocarcinoma"[tiab] OR "Adenocarcinoma of Ovary"[tiab] OR "Adenocarcinoma of the Ovary"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-13	pubmed
Last 12 months	2025-09-13 → 2026-09-13	45	`("Ovarian Adenocarcinoma"[tiab] OR "Adenocarcinoma of Ovary"[tiab] OR "Adenocarcinoma of the Ovary"[tiab]) AND (2025/09/13:2026/09/13[dp])`	2026-09-13	pubmed

Data updated 18 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (10)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 1–10 of 10 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
· Oncotarget · 2016 · PMID 26625204 · validated civic_curation pubmed
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
· J Ovarian Res · 2016 · PMID 27209210 · validated civic_curation pubmed
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
· J Clin Oncol · 2015 · PMID 26324360 · validated civic_curation pubmed
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.